Erbert Caceres, MD
Interventional Cardiology · Effingham, ILNPI 1508976788
Payments from drug & device makers
Across 201 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Amgen$639
- Johnson & Johnson$632
- Abiomed$358
- Abbott$346
- Novartis$286
- plus $2K from 27 others
What the payments were for
- Travel & lodging$1,12118%
- Food & beverage$5,04981%
- Education$461%
- Gifts$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 28 | $1,909 |
| Amgen | 23 | $639 |
| Johnson & Johnson | 35 | $632 |
| Abiomed | 4 | $358 |
| Abbott | 6 | $346 |
| Novartis | 23 | $286 |
| Penumbra, Inc. | 2 | $283 |
| Shockwave Medical, Inc | 11 | $268 |
| Pfizer | 9 | $136 |
| Endologix LLC | 1 | $134 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $128 |
| AstraZeneca | 8 | $122 |
| Novo Nordisk | 2 | $120 |
| Philips North America LLC | 3 | $103 |
| E.r. Squibb & Sons, L.L.C. | 7 | $97 |
| Regeneron Healthcare Solutions, Inc. | 4 | $92 |
| Biotronik Inc. | 4 | $73 |
| Bard Peripheral Vascular, Inc. | 1 | $69 |
| Edwards Lifesciences | 2 | $64 |
| Biosense Webster, Inc. | 2 | $56 |
| Cardiovascular Systems Inc. | 2 | $51 |
| Livanova USA, Inc. | 2 | $49 |
| Medtronic(2 entities) | 3 | $44 |
| Welch Allyn | 1 | $42 |
| Getinge USA Sales, LLC | 2 | $34 |
| Terumo Medical Corporation | 1 | $24 |
| Recor Medical Inc | 1 | $17 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Cardinal Health 200 LLC | 1 | $15 |
| Cook Medical LLC | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$247
- Impella$237
- Penumbra System$150
- AVVIGO Guidance System$141
- Ovation$134
- AFX$134
- Indigo System$133
- ESPRIT$123
- LUX-Dx Insertable Cardiac Monitor$113
How this compares
$6,259 in reported general payments places this provider in the 40th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 196 | $183,679 |
| Repatha SureclickEvolocumab | 148 | $106,761 |
| Praluent PenAlirocumab | 75 | $61,889 |
| EntrestoSacubitril/Valsartan | 52 | $56,224 |
| XareltoRivaroxaban | 38 | $41,474 |
| BrilintaTicagrelor | 28 | $20,091 |
| Repatha SyringeEvolocumab | 33 | $18,273 |
| FarxigaDapagliflozin Propanediol | 12 | $5,179 |
| Icosapent Ethyl | 19 | $4,376 |
| Ezetimibe | 168 | $4,012 |
| Ranolazine ErRanolazine | 32 | $3,687 |
| Nifedipine ErNifedipine | 175 | $3,492 |
| Clonidine | 26 | $3,435 |
| Metoprolol Succinate | 291 | $3,224 |
| Losartan Potassium | 279 | $2,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $136 | $183,679196 claims |
| NovartisEntresto | $286 | $56,22452 claims |
| Johnson & JohnsonXarelto | $632 | $41,47438 claims |
| AstraZenecaBrilinta, Farxiga | $122 | $25,27140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Effingham
- Charles DavidsonChicago$5.8M
- Ravi RamanaPalos Park$2.8M
- Mark RicciardiEvanston$2.2M
- Andrei PopElk Grove Village$1.9M
- Krishna Rocha SinghSpringfield$1.7M
- Bruce LewisMaywood$1.3M
- Justin LevisayEvanston$837K
- Atman ShahChicago$794K
- Laura DavidsonChicago$661K
- Sunil AgarwalSpringfield$609K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.